 |
|
|
| |
Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection With and Without Cirrhosis
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Kazuaki Chayama1, Fumitaka Suzuki2, Ken Sato3, Tomofumi Atarashi4, Tsunamasa Watanabe5, Hidenori Toyoda6, Masanori Atsukawa7, Atsushi Naganuma8,
Kazuo Notsumata9, Yukio Osaki10, Makoto Nakamuta11, Koichi Takaguchi12, Satoru Saito13, Koji Kato14, David L Pugatch14, Margaret Burroughs14, Rebecca Redman14, Katia Alves14, Tami J Pilot-Mati as14, Bo Fu14, Hiromitsu Kumada2
1Hiroshima University Hospital, Hiroshima, Japan; 2Toranomon Hospital, Tokyo, Japan; 3Gunma University Hospital, Maebashi, Japan; 4JA Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan; 5St. Marianna University School of Medicine, Kawasaki, Japan; 6Ogaki Municipal Hospital, Ogaki, Japan; 7Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan; 8NHO Takasaki General Medical Center, Takasaki, Japan; 9Fukuiken Saiseikai Hospital, Fukui, Japan; 10Osaka Red Cross Hospital, Osaka, Japan; 11NHO Kyushu Medical Center, Fukuoka, Japan; 12Kagawa Prefectural Central Hospital, Takamatsu, Japan; 13Yokohama City University Hospital, Yokohama, Japan; 14AbbVie Inc., North Chicago, Illinois, United States
|
| |
|
|
|
|
|
